This site uses cookies to measure how you use the website so it can be updated and improved based on your needs and also uses cookies to help remember the notifications you’ve seen, like this one, so that we don’t show them to you again. If you could also tell us a little bit about yourself, this information will help us understand how we can support you better and make this site even easier for you to use and navigate.

New insights into clinical trial for Colostrinin in Alzheimer’s disease


Szaniszlo, P., German, P., Hajas, G., Saenz, D. N., Kruzel, M., Boldogh, I.


The Journal Of Nutrition, Health & Aging, Volume: 13, No.: 3, Pages.: 235-241

Year of Publication



Background: The pathomechanism of Alzheimer’s disease (AD) is multifactorial although the most popular hypotheses are centered on the effects of the misfolded, aggregated protein, amyloid beta (Abeta) and on Tau hyperphosphorylation.; Objectives: Double blinded clinical trials were planned to demonstrate the effect of Colostrinin (CLN) on instrumental daily activities of AD patients. The potential molecular mechanisms by which CLN mediates its effects were investigated by gene expression profiling.; Methods: RNAs isolated from CLN-treated cells were analyzed by high-density oligonucleotide arrays. Network and pathway analyses were performed using the Ingenuity Pathway Analysis software.; Results: The Full Sample Analysis at week 15 showed a stabilizing effect of CLN on cognitive function in ADAS-cog (p = 0.02) and on daily function in IADL (p = 0.02). The overall patient response was also in favor of CLN (p = 0.03). Patients graded as mild on entry also showed a superior response of ADAS-cog compared to more advanced cases (p = 0.01). Data derived from microarray network analysis show that CLN elicits highly complex and multiphasic changes in the cells’ transcriptome. Importantly, transcriptomal analysis showed that CLN alters gene expression of molecular networks implicated in Abeta precursor protein synthesis, Tau phosphorylation and increased levels of enzymes that proteolitically eliminate Abeta. In addition, CLN enhanced the defense against oxidative stress and decreased expression of inflammatory chemokines and cytokines, thereby attenuating inflammatory processes that precede Alzheimer’s and other neurological diseases.; Conclusion: Together these data suggest that CLN has promising potential for clinical use in prevention and therapy of Alzheimer’s and other age-associated central nervous system diseases.;


activities of daily living, alzheimer disease, cells cultured, cognition, colostrinin, double-blind method, drug effects, drug therapy, gene expression, gene expression profiling, genetics, humans, methods, middle aged, neuroprotective agents, oligonucleotide array sequence analysis, peptides, severity of illness index, therapeutic use

Countries of Study


Types of Dementia

Alzheimer’s Disease

Types of Study

Randomised Controlled Trial

Type of Outcomes

ADLs/IADLs, Cognition

Type of Interventions

Pharmaceutical Interventions

Pharmaceutical Interventions